Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications-Reference-Cited by-同舟云学术

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Published:2016-03-03 Issue:4 Volume:15 Page:628-639
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Ardini Elena,Menichincheri Maria,Banfi Patrizia,Bosotti Roberta,De Ponti Cristina,Pulci Romana,Ballinari Dario,Ciomei Marina,Texido Gemma,Degrassi Anna,Avanzi Nilla,Amboldi Nadia,Saccardo Maria Beatrice,Casero Daniele,Orsini Paolo,Bandiera Tiziano,Mologni Luca,Anderson David,Wei Ge,Harris Jason,Vernier Jean-Michel,Li Gang,Felder Eduard,Donati Daniele,Isacchi Antonella,Pesenti Enrico,Magnaghi Paola,Galvani Arturo

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 256 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals;Current Problems in Cancer;2024-12

2. Macrocyclic-based strategy in drug design: From lab to the clinic;European Journal of Medicinal Chemistry;2024-11

3. Unraveling the enigma: Probing the unconventional binding site and binding mechanism of entrectinib with human serum albumin through spectroscopic, molecular docking, and dynamic simulation analyses;Journal of Molecular Liquids;2024-09

4. Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors;European Journal of Medicinal Chemistry;2024-09

5. The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions;Cancers;2024-08-19